The company has analysed the data and reported their conclusions. This does need to be looked at objectively but surely they understand sufficiently to give reasoned analysis - which they indicate the results are significant. I read that there are bright spots but proof of pudding is BIT taking it further. Encouraged by following statements in conclusion comments in the poster:
"The BIT225 cohort had a significantly greater reduction of the macrophage activation marker sCD163, a good indicator of all cause morbidity and mortality in HIV-1 patients. Additional reduction of this marker in patients taking BIT225 demonstrates significant immunological benefit.
In particular:
The commencement of a decline of activated CD4+ cell levels at week 6 suggests that virus from these reservoir cells is being eradicated, and cleared by week 12 when levels return to those seen in the ART + placebo cohort."
Still, DYOR but guilty of picking up some low priced OBs this morning
